Director/PDMR Shareholding

RNS Number : 5165D

GlaxoSmithKline PLC

19 February 2020

 

GlaxoSmithKline plc   (the ' Company ')

Vesting of Deferred Annual Bonus Plan Mandatory and Matching Awards

This notification sets out the vesting details for the Chief Executive Officer and other Persons Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus Awards over Ordinary Shares and American Depositary Shares ('ADSs') made in 2017 under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan ('DABP') and the associated Matching Awards, which were subject to relevant business performance conditions. The three-year performance period for the 2017 Matching Awards commenced on 1 January 2017 and ended on 31 December 2019. 

The performance measure vesting details for the DABP Matching Awards are as follows:

		Outcome and Vesting Level
Portion of the Award	Measure and Outcome	% of maximum	% of award
1/3rd	Adjusted Free Cash Flow - For the three-year period, the Company achieved Adjusted Free Cash Flow calculated in accordance with the principles for the measure of £13bn, which is above the level of £12.95bn required for maximum vesting.  Adjustments to the original target and vesting schedule were communicated in the 2018 Annual Report.	100	33.333
1/3rd	Total Shareholder Return - For the three years ending 31 December 2019, the Company's Total Shareholder Return ranked 8th, which is below the threshold vesting level against a comparator group of 10 global pharmaceutical companies including GSK.	0	0
1/3rd	R&D New Products - For the three-year period, the Company achieved New Product sales calculated in accordance with the principles for the measure of £7.254bn, which is above the level of £5.099bn required for maximum vesting.  The threshold level was £4.172bn.	100	33.333
	Total vesting for 2017 award Lapsed		66.666% 33.334%

 

The notifications that follow are for awards made to the Chief Executive Officer and other PDMRs.  They show the vesting of the Deferred Annual Bonus Awards including dividends accrued, and the proportion vesting in respect of the associated Matching Awards i.e. conditional awards that vested according to performance, including dividends accrued. The balance of the Matching Award made to each PDMR has lapsed.

The vesting date for awards over Ordinary Shares was 17 February 2020. The vesting date for awards over ADSs was 18 February 2020. The closing prices of Ordinary Shares and of ADSs of GlaxoSmithKline plc on their respective vesting dates were £16.616 and $43.55.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The number of Ordinary Shares released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	37,221 (Deferred)
			£0.00	24,815 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	62,036 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The number of Ordinary Shares released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	19,375 (Deferred)
			£0.00	12,917 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	32,292  £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The number of Ordinary Shares released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	12,243 (Deferred)
			£0.00	8,163 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	20,406  £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	The number of ADSs released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$0.00	7,116 (Deferred)
			$0.00	4,745 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	11,861 $0.00
e)	Date of the transaction	2020-02-18
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The number of Ordinary Shares released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00.	15,407 (Deferred)
			£0.00	10,273 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	25,680  £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The number of Ordinary Shares released on awards granted in 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,302 (Deferred)
			£0.00	4,869 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	12,171 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

 

END

 

 

DSHQKLFFBLLLBBB